22nd Century Group, Inc. (NASDAQ:XXII) Short Interest Update

22nd Century Group, Inc. (NASDAQ:XXII) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 286,600 shares, an increase of 17.5% from the November 15th total of 243,900 shares. Based on an average daily volume of 9,340,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.7% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on 22nd Century Group in a report on Friday. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 22nd Century Group stock. Anson Funds Management LP bought a new position in 22nd Century Group, Inc. (NASDAQ:XXII) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,140,452 shares of the biotechnology company’s stock, valued at approximately $691,000. Anson Funds Management LP owned about 6.77% of 22nd Century Group as of its most recent filing with the Securities and Exchange Commission (SEC). 18.06% of the stock is currently owned by institutional investors.

22nd Century Group Stock Down 33.2 %

Shares of NASDAQ XXII opened at $0.05 on Friday. The firm has a market cap of $2.28 million, a P/E ratio of 0.00 and a beta of 1.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.93 and a current ratio of 1.09. 22nd Century Group has a 1 year low of $0.04 and a 1 year high of $4.31. The firm’s 50 day moving average price is $0.11 and its 200 day moving average price is $0.42.

22nd Century Group’s stock is going to reverse split on Tuesday, December 17th. The 1-135 reverse split was announced on Friday, December 13th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 16th.

22nd Century Group (NASDAQ:XXII) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.54) EPS for the quarter. 22nd Century Group had a negative net margin of 144.09% and a negative return on equity of 380.39%. The business had revenue of $5.95 million during the quarter.

22nd Century Group Company Profile

22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.